LON:OKYO OKYO Pharma (OKYO) Share Price, News & Analysis → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Free OKYO Stock Alerts GBX 1.40 -0.45 (-24.32%) (As of 05/19/2023) Add Compare Share Share Today's Range 1.40▼ 1.9850-Day Range 1.40▼ 1.4052-Week Range 1.35▼ 8.50Volume364,142 shsAverage Volume431,999 shsMarket Capitalization£23.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesInsider TradesStock AnalysisHeadlinesInsider Trades Get OKYO Pharma alerts: Email Address Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About OKYO Pharma Stock (LON:OKYO)OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.Read More OKYO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OKYO Stock News HeadlinesApril 17, 2024 | americanbankingnews.comOKYO Pharma (LON:OKYO) Stock Price Down 24.3%March 31, 2024 | msn.comA second Kobayashi Pharma Japan factory inspected over deathsApril 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!March 31, 2024 | msn.comJapanese authorities inspect second Kobayashi Pharma factory after deathsMarch 30, 2024 | msn.comKobayashi factory searched over deaths possibly linked to supplementsMarch 29, 2024 | msn.com5 dead and over 100 hospitalized from recalled Japanese health supplementsMarch 28, 2024 | msn.comWhat are 'beni-koji' products linked to Japan deaths?March 27, 2024 | msn.comA Japanese supplement pill is recalled after two people died and more than 100 were hospitalizedApril 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!March 14, 2024 | msn.comUnicycive rises 4% on $50M private placementMarch 3, 2024 | msn.comPeople in Japan more worried about smell of others' excrement than their own: surveyFebruary 23, 2024 | msn.com1 in 4 Japan primary school kids with hay fever's itchy eyes have trouble studyingFebruary 22, 2024 | benzinga.comOKYO Pharma Stock (NASDAQ:OKYO), Short Interest ReportFebruary 9, 2024 | msn.comOKYO Pharma gains on receiving FDA nod of IND for OK-101 in neuropathic corneal painFebruary 9, 2024 | morningstar.comOKYO Shares Rise 12% After FDA Clearance for IND ApplicationJanuary 8, 2024 | markets.businessinsider.comOKYO Pharma Says Phase 2 Study Of OK-101 Did Not Meet Primary GoalJanuary 5, 2024 | finance.yahoo.comOKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024December 4, 2023 | proactiveinvestors.comEyepoint Pharmaceuticals stock soars on wet-AMD trial resultsDecember 4, 2023 | finance.yahoo.comOKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol VisitNovember 3, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of OKYO Pharma Limited - (OKYO) with Buy RecommendationOctober 31, 2023 | proactiveinvestors.comOKYO Pharma raises $5.84m via share issuanceOctober 31, 2023 | finanznachrichten.deOKYO Pharma Announces $5.84 Million Cash Raise and Payables ReductionOctober 5, 2023 | msn.comDry Eye Disease Affects Around 50M Americans, OKYO Pharma's Candidate Shows Safety In Mid-Stage StudyOctober 5, 2023 | msn.comOKYO shares retreat 12% after rallying ahead of Phase 2 study updateOctober 5, 2023 | markets.businessinsider.comOKYO Pharma Reports Positive Safety Data Profile For OK-101 In Dry Eye DiseaseOctober 5, 2023 | proactiveinvestors.comOKYO Pharma phase II dry eye trial making encouraging progressOctober 5, 2023 | finance.yahoo.comOKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")See More Headlines Receive OKYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:OKYO CUSIPN/A CIKN/A Webwww.okyopharma.com Phone44 20 7495 2379FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-6,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-397.13% Return on Assets-154.72% Debt Debt-to-Equity Ratio1.65 Current Ratio0.83 Quick Ratio2.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.05 per share Price / Cash Flow28.00 Book ValueGBX (1) per share Price / Book-1.40Miscellaneous Outstanding Shares1,660,000,000Free FloatN/AMarket Cap£23.24 million OptionableNot Optionable Beta-0.06 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Gary S. Jacob Ph.D. (Age 75)CEO & Exec. Director Comp: $311kMr. Michael Paul Beck (Age 65)Founder Ms. Keeren Shah (Age 45)Chief Financial Officer Dr. Rajkumar Patil Ph.D. (Age 64)Chief Scientific Officer Key CompetitorsC4X DiscoveryLON:C4XDSareumLON:SARHemogenyx PharmaceuticalsLON:HEMODestiny PharmaLON:DESTAorTech InternationalLON:AORView All Competitors OKYO Stock Analysis - Frequently Asked Questions How have OKYO shares performed in 2024? OKYO Pharma's stock was trading at GBX 1.40 on January 1st, 2024. Since then, OKYO stock has increased by 0.0% and is now trading at GBX 1.40. View the best growth stocks for 2024 here. How do I buy shares of OKYO Pharma? Shares of OKYO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:OKYO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
